Conferences
#ESHERYTHRO2021

2nd Translational Research Conference

Erythropoiesis Control and Ineffective Erythropoiesis:
from bench to bedside

‍

#ESHERYTHRO2021
Translational
March 5-7, 2021
-
E-Conference

Chairs: Maria Domenica Cappellini, Stuart Orkin, Valeria Santini

2nd Translational Research Conference

Erythropoiesis Control and Ineffective Erythropoiesis:
from bench to bedside

‍

Information

‍

ABOUT THE CONFERENCE:

The main objective of this virtual conference is to accompany you from “bench to bedside”, translating recent progress in the understanding of the origin and developmental control of haemopoietic megakaryocytic-erythroid progenitors into clinical practice.

Erythropoiesis is a complex multistep process from the committed erythroid progenitor to the mature red cell, that involves cross talk with other haemopoietic progenitors. Although recent advances have shed light on some components of this process, much still remains to be elucidated, in particular in the context of pathological erythropoiesis and in haematological disorders characterized by ineffective erythropoiesis.

During erythropoiesis, efficient cytoprotective systems are required to limit possible reactive oxygen species (ROS) related toxic effects. The role of these systems is even more important in conditions of ineffective erythropoiesis (IE) such as thalassaemias, sickle cell disease and congenital dyserythropoietic anaemias (CDAs), but also in myelodysplastic syndromes (MDS).

To date, blood transfusions and erythropoiesis stimulating agents (ESAs) such as recombinant EPO, are the frontline therapies for anaemia associated with ineffective erythropoiesis (IE). However, neither of these treatments are without risk and in some cases they are not effective. There is therefore a clinical need for novel agents with different mechanisms of action from those of existing ESAs. Furthermore, gene therapy and genome editing are becoming a reality for some erythropoietic disorders, opening a new therapeutic scenario and creating needs for decision-making approaches and continuing education.

All of these exciting, rapidly evolving issues will be discussed in the translational setting of this e-Conference, supported by the combined expertise of a distinguished faculty of global experts in the field, including basic scientists and clinicians.

‍

SCIENTIFIC TOPICS:

– Bone marrow response to viral infections
– Hematological response to SARS CoV2 infection
– Dyserythropoiesis in clonal hematopoiesis and MDS
– Erythropoiesis Control
– Iron metabolism and erythropoiesis
– Inherited dyserythropoiesis
– Drugs and ineffective erythropoiesis
– Gene Therapy/Editing

‍

Programme

Read the final programme!

CLICK HERE
ON-DEMAND CONTENT AVAILABLE
CLICK HERE

Corporate partners

With the support of*:

‍

‍

Level 1 E-Conference Partner
*******

‍

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.

‍

‍

Advancing haematology through international leading-edge disease- focused conferences.

Explore a portfolio of leading-edge scientific, translational research and clinically oriented meetings, designed to foster scientific exchange, practical insight, education and collaboration across clinical and research fields.
Explore all conferences